Key result
Melatonin cuts reperfusion VT/VF by ~40 percentage points vs placebo in rat ischemia.
Why the study?
Melatonin is assumed to confer cardioprotective action via antioxidative properties, but the association between its antiarrhythmic, electrophysiological, and antioxidative effects in ischemia/reperfusion is unclear.
Absolute Event Rate: 29% vs 69%
p-value: p=0.020
Melatonin attenuated reperfusion arrhythmias in rats; hypothesis-generating and requires clinical validation before human use.
Melatonin is assumed to confer cardioprotective action via antioxidative properties. We evaluated the association between ventricular tachycardia and/or ventricular fibrillation (VT/VF) incidence, oxidative stress, and myocardial electrophysiological parameters in experimental ischemia/reperfusion under melatonin treatment. Melatonin was given to 28 rats (10 mg/kg/day, orally, for 7 days) and 13 animals received placebo. In the anesthetized animals, coronary occlusion was induced for 5 min followed by reperfusion with recording of unipolar electrograms from ventricular epicardium with a 64-lead array. Effects of melatonin on transmembrane potentials were studied in ventricular preparations of 7 rats in normal and “ischemic” conditions. Melatonin treatment was associated with lower VT/VF incidence at reperfusion, shorter baseline activation times (ATs), and activation-repolarization intervals and more complete recovery of repolarization times (RTs) at reperfusion (less baseline-reperfusion difference, ΔRT) (p < 0.05). Superoxide dismutase (SOD) activity was higher in the treated animals and associated with ΔRT (p = 0.001), whereas VT/VF incidence was associated with baseline ATs (p = 0.020). In vitro, melatonin led to a more complete restoration of action potential durations and resting membrane potentials at reoxygenation (p < 0.05). Thus, the antioxidative properties of melatonin were associated with its influence on repolarization duration, whereas the melatonin-related antiarrhythmic effect was associated with its oxidative stress-independent action on ventricular activation.
No takes yet. Share an insight, caveat, or question.
Sedova et al. (2019) studied Myocardial ischemia/reperfusion (n=41). Melatonin vs. Placebo was evaluated on Ventricular tachycardia and/or ventricular fibrillation (VT/VF) incidence at reperfusion (p=0.020). Melatonin reduced the incidence of ventricular tachycardia and ventricular fibrillation during reperfusion to 29% compared to 69% with placebo (p=0.020) in a rat myocardial ischemia model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: